Research and Markets: Physician Survey Indicates Increased Use of Lidoderm Likely to Fuel Above-Consensus Sales Growth.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c42735) has announced the addition of the new report from Datamonitor "Financial Markets Research: Endo Pharmaceuticals' Lidoderm - Physician Survey Indicates Increased Use Likely to Fuel Above-consensus Sales Growth" to their offering. Launched in the US in 1999 as the only topical lidocaine lidocaine /li·do·caine/ (li´do-kan) an anesthetic with sedative, analgesic, and cardiac depressant properties, applied topically in the form of the base or hydrochloride salt as a local anesthetic; also used in the latter form as a patch, Lidoderm has demonstrated very strong growth year-on-year, with annual growth of 114% in 2003, 73% in 2004, and 36% in 2005. Lidoderm's continued growth in both labelled and off-label indications is highly important to the company's future success. Scope of this title: This title provides an analysis of current and future use of Lidoderm across several chronic pain conditions by the physician specialties that treat the bulk of patients. We surveyed 31 physicians including pain specialists, neurologists This is a list of the most important neurologists, with their dates of birth and death and nationality.
n. Abbr. GP A physician whose practice consists of providing ongoing care covering a variety of medical problems in patients of all ages, often including referral to appropriate specialists. in the course of research. Report Highlights Include: Surveyed physicians expect to continue to increase their use of Lidoderm in post-herpetic neuralgia Post-herpetic neuralgia Lingering pain that can last for years after an attack of shingles. Mentioned in: Electrical Nerve Stimulation and a variety of off-label pain conditions with use varying by specialty. The largest barriers to use of Lidoderm are price and reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. but some physicians believe the situation is improving. Near-term competitive threats are not expected to substantially derail de·rail intr. & tr.v. de·railed, de·rail·ing, de·rails 1. To run or cause to run off the rails. 2. Lidoderm's growth rate. Reasons to order your copy: This title enables readers to understand the commercial potential for Endo Pharmaceutical's Lidoderm based on a multi-specialty physician survey. It anticipates likely changes in the future market dynamics for pain therapies following the likely success of Lidoderm. Lidoderm: Lidoderm is the only topical lidocaine patch available in the US. Lidoderm is FDA-approved in post-herpetic neuralgia but has data in other pain indications. Five years post-launch, Lidoderm sales are still showing strong growth. Physician Survey Background: Pain specialists are the highest prescribers of Lidoderm Use of Lidoderm: Physicians report increasing use of Lidoderm on- and off-label. All surveyed physician types expect to prescribe greater volumes of Lidoderm. Lidoderm continues to penetrate approved indication approved indication, n 1. reliable signs that a certain remedy should be used. Not synonymous with “authorized.” 2. FDA-approved condition for a drug or other treatment that allows labeling. and low back pain, its largest off-label condition. In PHN Postherpetic neuralgia (PHN) The term used to describe the pain after the rash associated with herpes zoster is gone. Mentioned in: Shingles PHN Postherpetic neuralgia, see there , pain specialists have levelled off use at 60% of patients, while other specialists predict increases. Lidoderm share of low back pain market expected to expand across all physician types. Drivers of Lidoderms Growth: Survey results indicate Lidoderm growth fuelled by both new and existing prescribers. Growing physician familiarity and appreciation of benign safety profile drive use. Increased marketing and publication of off-label data also spur growth. Lidoderm detailing has become more frequent, especially for neurologists. Price and reimbursement barriers exist, but some physicians report improvements. Pfizer's Lyrica, a recent entrant en·trant n. One that enters, especially one that enters a competition. [French, from present participle of entrer, to enter, from Old French; see enter. to pain market poses little competitive threat. Efficacy results from ongoing low back pain trial likely to only be moderately important. For more information visit http://www.researchandmarkets.com/reports/c42735 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion